<DOC>
	<DOCNO>NCT02597946</DOCNO>
	<brief_summary>investigate effectiveness safety afatinib advance NSCLC patient HER2 mutation , previously treat 1 2 chemotherapy regimen</brief_summary>
	<brief_title>Afatinib NSCLC With HER2 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Patients Histologically cytologically confirm diagnosis stage IV NSCLC ( AJCC 7.0 ) , fail one two chemotherapy regimen , one must platinumbased . Tumor tissue HER2 mutation confirm AmoyDxÂ® HER2 Mutation Detection Kit Patients least one measurable tumor lesion accurately measure CT scan MRI accord RECIST 1.1 Age &gt; =18 year ECOG performance score 0 1 Adequate organ function Recovered previous therapy relate toxicity &lt; =Grade 1 study entry ( except stable sensory neuropathy &lt; =Grade 2 alopecia ) Written inform consent consistent ICHGCP local GCP guideline Inclusion criterion Part B Adequate organ function , inclusion criterion No.6 ECOG performance score 0~2 More 12 week clinical benefit ( PR , CR , SD ) part A Further inclusion criterion apply Exclusion criterion : Prior treatment EGFR HER2 target small molecule antibody . Any chemo , immune anticancer therapy within 4 week prior start study treatment , Hormonal treatment within 2 week prior start study treatment , Radiotherapy within 4 week prior start treatment , except follow : . ) Palliative radiation target organ chest may allow 2 week prior enter , ii . ) Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . Major surgery within 4 week start study treatment schedule surgery project course study Known hypersensitivity afatinib excipients trial drug History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification &gt; = 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior randomisation . Any history concomitant condition , opinion Investigator , would compromise patient 's ability comply study interfere evaluation efficacy safety test drug . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . Requiring treatment prohibit concomitant medication Known preexist interstitial lung disease . Any history presence poorly control gastrointestinal disorder could affect absorption study drug . Active hepatitis B infection and/or active hepatitis C infection and/or know HIV carrier . Leptomeningeal carcinomatosis . Symptomatic brain metastasis ; To eligible patient must asymptomatic brain metastasis least 4 week without requirement steroid antiepileptic therapy . Women childbearing potential ( WOCBP ) men able father child , unwilling abstinent use highly effective method birth control duration study participation least 2 week treatment end . Women pregnant , nursing , plan become pregnant trial Exclusion criterion Part B Any known contraindication paclitaxel treatment . Not able tolerate low dose afatinib . Peripheral polyneuropathy &gt; Grade 2 Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>